Status:
UNKNOWN
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Lead Sponsor:
Assiut University
Conditions:
Adult Acute Myeloid Leukemia
Eligibility:
All Genders
18-50 years
Brief Summary
1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML. 2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.
Detailed Description
1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients. 2. CD56 antigen expression, an inexpensive, easy to detect and re...
Eligibility Criteria
Inclusion
- Anew diagnosis cases of adult AML
Exclusion
- Pediatric AML .
- follow up cases of adult AML
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03283228
Start Date
December 1 2017
End Date
October 1 2019
Last Update
September 14 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.